3Saw SM, Gazzard G, Friedman DS. Interventions for angle-closure glaucoma: an evidence-based update. Ophthalmology, 2003, 110 :1869-1878.
4Chew PT, Aung T, Aquino MV, et al. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology ,2004,111:427-434.
5Aung T, Wong HT, Yip CC, et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.Ophthalmology,2000,107 : 1178-1183.
6Orzalesi N, Rossetti L, Invemizzi T, et al. Effect of timolol,latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci ,2000,41:2566-2573.
7Camras CB, Alm A, Watson PG. Latanoprost : a prostaglandin analog for glaucoma therapy. Ophthalmology, 1996,103 : 1916-1924.
8Stamper RL, Lieberman MF, Drake MV. Becker-shaffer's diagnosis and therapy of the glaucomas. 7th ed. Singapore: Harcourt Asia,1999. 500.
9Stamper RL, Lieberman MF, Drake MV. Becker-shaffer's diagnosis and therapy of the glaucomas. 7th ed. Singapore: Harcourt Asia,1999. 53.
10Kook MS,Cho HS,Yang SJ,et al. Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face:a preliminary study. J Ocul Pharmacol Ther,2005, 21:75-84.
10Daniel M. Albert,Ronald E. Gangnon,Michele L. Zimbric,Christine M. Damico,Marian R. Fisher,Joel Gleiser,Hans E. Grossniklaus,W. Richard Green,尚庆丽（译）,马景学（校）.拉坦前列腺素与非拉坦前列腺素治疗患者虹膜切除标本的组织病理学特征研究[J].美国医学会眼科杂志（中文版）,2005,17(3):131-136. 被引量：1
